Skip to main content
Article thumbnail
Location of Repository

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

By Christopher J. Duff, Martin J. Scott, Ian T. Kirby, Sue E. Hutchinson, Steve L. Martin and Nigel M. Hooper


PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes degradation of the LDLR [LDL (low-density lipoprotein) receptor] through an as-yet-undefined mechanism, leading to a reduction in cellular LDLc (LDL-cholesterol) and a concomitant increase in serum LDLc. Central to the function of PCSK9 is a direct protein–protein interaction formed with the LDLR. In the present study, we investigated a strategy to modulate LDL uptake by blocking this interaction using specific antibodies directed against PCSK9. Studies using surface plasmon resonance demonstrated that direct binding of PCSK9 to the LDLR could be abolished with three different anti-PCSK9 antibodies. Two of these antibodies were raised against peptide epitopes in a region of the catalytic domain of PCSK9 that is involved in the interaction with the LDLR. Such antibodies restored LDL uptake in HepG2 cells treated with exogenous PCSK9 and in HepG2 cells engineered to overexpress recombinant PCSK9. This latter observation indicates that antibodies blocking the PCSK9–LDLR interaction can inhibit the action of PCSK9 produced endogenously in a cell-based system. These antibodies also disrupted the higher-affinity interaction between the natural gain-of-function mutant of PCSK9, D374Y, and the LDLR in both the cell-free and cell-based assays. These data indicate that antibodies targeting PCSK9 can reverse the PCSK9-mediated modulation of cell-surface LDLRs

Topics: Research Article
Publisher: Portland Press Ltd.
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2009). 732 c The Authors Journal compilation c 2009 Biochemical Society ©
  2. (2007). Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.
  3. (2007). Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
  4. (2007). Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.
  5. (2005). Decreased plasma cholesterol and hypersensitivity to statins in mice lacking
  6. (2006). Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
  7. (2007). Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.
  8. (2007). Efficient expression of secretedproteasesviarecombinantBacMamvirus.ProteinExpressionPurif.52,104–116
  9. (2008). Emerging antidyslipidemic drugs.
  10. (2006). Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.
  11. (2008). Molecular basis for LDL receptor recognition by PCSK9.
  12. (2007). Molecular biology of PCSK9: its role in LDL metabolism.
  13. (2003). Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.
  14. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
  15. (2004). NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.
  16. (2005). Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
  17. (2008). PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
  18. (2008). PCSK9: an enigmatic protease.
  19. (2004). Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.
  20. (2006). Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
  21. (2007). Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.
  22. (2004). Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
  23. (2009). Structural and biochemical characterization of the wild type PCSK9/EGF-AB complex and natural FH mutants.
  24. (2007). Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
  25. (2007). The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
  26. (2007). The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.
  27. (2006). The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.
  28. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.
  29. (1999). Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.